Complement inactivation by recombinant human C3 derivatives

Journal of Immunology

Volumn 173, Issue 9, 2004, Pages 5540-5545

  Kölln, Johanna ^a   Spillner, Edzard ^a   Andrä, Jörg ^a,b   Klensang, Katrin ^a   Bredehorst, Reinhard ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COBROTOXIN; COMPLEMENT COMPONENT C3; RECOMBINANT HUMAN COMPLEMENT COMPONENT 3 DERIVATIVE; SNAKE VENOM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CATALYSIS; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENZYME MECHANISM; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 6344274705     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.173.9.5540     Document Type: Article

References (41)

1. Kemp, P. A., J. H. Spragg, J. C. Brown, B. P. Morgan, C. A. Gunn, and P. W. Taylor. 1992. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J. Clin. Lab. Immunol. 37:147.
2. Kirklin, J. K., S. Westaby, E. H. Blackstone, J. W. Kirklin, D. E. Chenoweth, and A. D. Pacifico. 1983. Complement and the damaging effects of cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 86:845.
3. Homeister, J. W., P. Satoh, and B. R. Lucchesi. 1992. Effects of complement activation in the isolated heart: role of the terminal complement components. Circ. Res. 71:303.
4. Hill, J. A., and P. A. Ward. 1971. The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J. Exp. Med. 133:885.
5. Weisman, H. F., T. Bartow, M. K. Leppo, H. C. Marsh, Jr., G. R. Carson, M. F. Concino, M. P. Boyle, K. H. Roux, M. L. Weisfeldt, and D. T. Fearon. 1990. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 249:146.
6. Evans, M. J., S. A. Rollins, D. W. Wolff, R. P. Rother, A. J. Norin, D. M. Themen, G. A. Grijalva, J. P. Mueller, S. H. Nye, S. P. Squinto, et al. 1995. In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Mol. Immunol. 32:1183.
7. Fiane, A. E., T. E. Mollnes, V. Videm, T. Hovig, K. Hogasen, O. J. Mellbye, L. Spruce, W. T. Moore, A. Sahu, and J. D. Lambris. 1999. Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor Compstatin. Transplant. Proc. 31:934.
8. Pangburn, M. K., and H. J. Müller-Eberhard. 1984. The alternative pathway of complement. Springer Semin. Immunopathol. 7:16.
9. Fearon, D. T., and K. F. Austen. 1975. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J. Exp. Med. 142:856.
10. Liszewski, M. K., and J. P. Atkinson. 1998. The Human Complement System in Health and Disease. J. E. Volanakis and M. M. Frank, eds. Marcel Dekker, New York, p 149.
11. Müller-Eberhard, H. J., and K. E. Fjellstrom. 1971. Isolation of the anticomplementary protein from cobra venom and its mode of action on C3. J. Immunol. 107:1666.
12. Vogel, C. W., and H. J. Müller-Eberhard. 1982. The cobra venom factor-dependent C3 convertase of human complement: a kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J. Biol. Chem. 257:8292.
13. Vogel, C. W., R. Bredehorst, D. C. Fritzinger, T. Grunwald, P. Ziegelmüller, and M. A. Kock. 1996. Structure and function of cobra venom factor, the complement-activating protein in cobra venom. Adv. Exp. Med. Biol. 391:97.
14. Fritzinger, D. C., R. Bredehorst, and C. W. Vogel. 1994. Molecular cloning and derived primary structure of cobra venom factor. Proc. Natl. Acad. Sci. USA 91:12775.
15. Medicus, R. G., O. Götze, and H. J. Müller-Eberhard. 1976. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway. J. Exp. Med. 144:1076.
16. Morgan, B. P., and C. L. Harris. 2003. Complement therapeutics: history and current progress. Mol. Immunol. 40:159.
17. Vogel, C. W., and H. J. Müller-Eberhard. 1984. Cobra venom factor: improved method for purification and biochemical characterization. J. Immunol. Methods 73:203.
18. Kölln, J., M. Matzas, N. Jänner, T. Mix, K. Klensang, R. Bredehorst, and E. Spillner. 2004. Functional analysis of cobra venom factor/human C3 chimeras transiently expressed in mammalian cells. Mol. Immunol. 41:19.
19. Ausubel, F. M. 1996. Current Protocols in Molecular Biology. Wiley Interscience, New York.
20. Ballow, M., and C. G. Cochrane. 1969. Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them. J. Immunol. 103: 944.
21. O'Keefe, M. C., L. H. Caporale, and C. W. Vogel. 1988. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor. J. Biol. Chem. 263:12690.
22. Alsenz, J., J. D. Becherer, B. Nilsson, and J. D. Lambris. 1990. Structural and functional analysis of C3 using monoclonal antibodies. Curr. Top Microbiol. Immunol. 153:235.
23. Garred, P., T. E. Mollnes, and M. D. Kazatchkine. 1989, Activation-dependent antigenic changes of human C3. Complement Inflamm. 6:205.
24. Lambris, J. D., D. Avila, J. D. Becherer, and H. J. Müller-Eberhard. 1988. A discontinuous factor H binding site in the third component of complement as delineated by synthetic peptides. J. Biol. Chem. 263:12147.
25. Fishelson, Z. 1991. Complement C3: a molecular mosaic of binding sites. Mol. Immunol. 28:545.
26. Alsenz, J., D. Avila, H. P. Huemer, I. Esparza, J. D. Becherer, T. Kinoshita, Y. Wang, S. Oppermann, and J. D. Lambris. 1992. Phytogeny of the third component of complement, C3: analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species. Dev. Comp. Immunol. 16:63.
27. Lambris, J. D., Z. Lao, T. J. Oglesby, J. P. Atkinson, C. E. Hack, and J. D. Becherer. 1996. Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. J. Immunol 156:4821.
28. Taniguchi-Sidle, A., and D. E. Isenman. 1994. Interactions of human complement component C3 with factor B and with complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) involve an acidic sequence at the N-terminus of C3 α′-chain. J. Immunol 153:5285.
29. Oran, A. E., and D. E. Isenman. 1999. Identification of residues within the 727-767 segment of human complement component C3 important for its interaction with factor H and with complement receptor 1 (CR1, CD35). J. Biol. Chem. 274:5120.
30. Schmidt, T. G., J. Koepke, R. Frank, and A. Skerra. 1996. Molecular interaction between the Strep-tag affinity peptide and its cognate target, streptavidin. J. Mol. Biol. 255:753.
31. DiScipio, R. G., C. A. Smith, H. J. Müller-Eberhard, and T. E. Hugli. 1983. The activation of human complement component C5 by a fluid phase C5 convertase. J. Biol. Chem. 258:10629.
32. Lachmann, P. J., and L. Halbwachs. 1975. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin. Exp. Immunol. 21:109.
33. Alper, C. A., and D. Balavitch. 1976. Cobra venom factor: evidence for its being altered cobra C3 (the third component of complement). Science 191:1275.
34. Andersson, J., K. N. Ekdahl, R. Larsson, U. R. Nilsson, and B. Nilsson. 2002. C3 Adsorbed to a polymer surface can form an initiating alternative pathway convertase. J. Immunol. 168:5786.
35. Nilsson, B., and U. R. Nilsson. 1986. SDS denaturation of complement factor C3 as a model for the allosteric modifications associated with C3b-binding: demonstration of a profound conformational change by means of circular dichroism and quantitative immunoprecipitation. Immunol. Lett. 13:11.
36. Kock, M. A. 1996. Expression and Characterisation of Recombinant Cobra Venom Factor. Wissenschaft und Technik Verlag Gross, Berlin.
37. Schmid, E., R. L. Warner, L. D. Crouch, H. P. Friedl, G. O. Till, T. E. Hugli, and P. A. Ward. 1997. Neutrophil chemotactic activity and C5a following systemic activation of complement in rats. Inflammation 21:325.
38. Wetsel, R. A., and W. P. Kolb. 1983. Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J. Exp. Med. 157:2029.
39. Bruggemann, M., G. Winter, H. Waldmann, and M. S. Neuberger. 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153.
40. Riechmann, L., M. Clark, H. Waldmann, and G. Winter. 1988. Reshaping human antibodies for therapy. Nature 332:323.
41. Hale, G., M. J. Dyer, M. R. Clark, J. M. Phillips, R. Marcus, L. Riechmann, G. Winter, and H. Waldmann. 1988. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 2:1394.